Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis
Methodological detailscase-based surveys, consensus framework, nominal group technique
- Case-based surveys
- Consensus framework
- Nominal group technique
Recommendations
As issued by the authors
Four bDMARD consensus treatment plans (CTPs) proposed: TNFα inhibitor (adalimumab or infliximab), abatacept, rituximab and tocilizumab; each with different dosing and/or route options
Among 76 respondents, consensus achieved for the proposed CTPs (93% [67 of 72]) and for patient characteristics, assessments, outcome measures and follow-up
By weighted average, respondents would most likely administer rituximab, then abatacept, TNFα inhibitor and tocilizumab
Original publication
Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). Published 14 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →